(Q37687874)

22 August 2017

1 reference

title

Future biologic targets for IBD: potentials and pitfalls (English)

1 reference

22 August 2017

2

Stephan R Targan

1 reference

22 August 2017

Gil Y Melmed

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Nature Reviews Gastroenterology & Hepatology

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

110-117

1 reference

The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

C-reactive protein: anti-placebo or predictor of response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Natalizumab for active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

JC virus leukoencephalopathy complicating Wegener’s granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Efficacy of an inhibitor of adhesion molecule expression (GI270384X) in the treatment of experimental colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Immunopathogenesis of inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Recent advances in IBD pathogenesis: genetics and immunobiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Crohn's disease: beyond antagonists of tumour necrosis factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Biological therapies for inflammatory bowel diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Targeting signal transduction as a strategy to treat inflammatory diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Anti-interleukin-12 antibody for active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Genetics of ulcerative colitis: the come-back of interleukin 10

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

31 March 2020

12 December 2020

Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

New insights into the pathogenesis of inflammatory bowel disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

NOD-like receptors and human diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Crohn's disease is associated with a toll-like receptor-9 polymorphism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Bacterial flagellin is a dominant antigen in Crohn disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Predictors of early response to infliximab in patients with ulcerative colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Personalized medicine and inhibition of EGFR signaling in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

Screening for epidermal growth factor receptor mutations in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.218

OTI-010 Osiris Therapeutics/JCR Pharmaceuticals

31 March 2020

1 reference

PubMed

12 December 2020

The effect of diversion of intestinal contents on the progress of Crohn's disease of the large bowel

1 reference

PubMed

12 December 2020

CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders

1 reference

PubMed

12 December 2020

10.1038/NRGASTRO.2009.218

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1018880982

0 references

1 reference